IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bryan, et al.	LAP20Res'dPGT/PTO 11 MAY 2006
Serial No. To Be Assigned	Art Unit:
Filed: May 11, 2006 For: OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST	Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Christin Cuffe Date 5-11-06

INFORMATION DISCLOSURE STATEMENT

1 MAY 2006

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION			
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE		
		<u> </u>		
If this is inconvenient, additional copies will be submitted upon reque	st.			
6. In accordance with 37 C.F.R. 1.97, (check one)				
the attached information is filed within three months of the filing d	ate of the captioned case.			
the attached information is filed more than three months after the Office Action on the merits.	filing date but prior to the n	nailing of a first		

the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114. the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p). each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement. no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement. Respectfully submitted By: Alysia A. Finnegan Attorney For Applicant(s) Reg. No. 48,878 MERCK & CO., INC. Patent Dept., RY60-30 P.O. Box 2000 Rahway, N.J. 07065-0907

(732)594-<u>2583</u>

Date: May 11, 2006

					Tach and Tracellar Office, 0.5 Del 74 (Tricel Co. Collabore			
Su	Substitute for form 1449A/PTO			COMPLETE IF KNOWN				
INFORMATION DISCLOSURE				Application Number	To Be Assigned / 579 111			
0			DIICANE	Filing Date	May 11, 2006			
5	TATEMENT BY	AP	PLICANI	First Named Ingentor	1 MAY 2006			
				Group Art Unit				
	(use as many sheets	as n	ecessary)	Examiner Name				
Sheet	1	of	3	Attorney Docket Number	21561P			
_								

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY					
		5,821,087		Lowe, et al.	10/13/1998					
		6,159,729		Hofmann, et al.	12/12/2000					
			<u> </u>							
			_							
					-					
					-					
			-							
			1							

	FOREIGN PATENT DOCUMENTS							
	<u> </u>		Foreign Patent Document			Date of Publication of		
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY		
		PCT	WO 98/34640		Merck & Co., Inc.	08/13/1998		
		PCT	WO 99/02694		The University of Queensland	01/21/1999		
		PCT	WO 00/09157		Merck & Co., Inc.	02/24/2000		
		PCT	WO 01/14416 A2		Merck & Co., Inc.	03/01/2001		
		PCT	WO 02/08435 A1		Glaxo Group Limited	01/31/2002		
		PCT	WO 2004/084831 A2		Merck & Co., Inc.	10/07/2004		
		PCT	WO 2005/032586		Merck & Co., Inc.	04/14/2005		

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/0SA (07-05). Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

haditude for form 1440R/DTO			COMPLETE IF KNOWN						
		CLOSURE	Application Number	To Be Assigned 2019 1 1					
TO A TORONAL TONIAN TO	N A D	DI ICANIT	Filing Date	May 11, 2006					
IAIEMENIE) I AF	PLICANI	First Named Inventor	Bryan, et al.					
,			Group Art Unit						
(use as many sne	eis as n	ecessary)	Examiner Name						
2	of	3	Attorney Docket Number	21561P					
	NFORMATION TATEMENT E	TATEMENT BY AP	NFORMATION DISCLOSURE TATEMENT BY APPLICANT (use as many sheets as necessary)	TATEMENT BY APPLICANT (use as many sheets as necessary) Application Number Filing Date First Named Inventor Group Art Unit Examiner Name					

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
		Bosch, et al., "The casual relation between human papillomavirus and cervical cancer", J. Clin. Path., Vol. 55, pp. 244-265, 2002.					
		Breitburd, et al., "Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect against Experimental CRPV Infection", J. of Virol., Vol. 69, No. 6, June 1995, pp. 3959-3963.					
		GenBank Accession No. NC_001443.					
		Guo, et al., "Signals Sufficient for 3'-End Formation of Yeast mRNA", Mol and Cell Biology, Vol. 16, No. 6, pp. 2772-2776, June 1996.					
5		Guo, et al., "3'-end-forming signals of yeast mRNA", TIBS 21, pp. 477-481.					
		Heidmann, et al., "Flexibility and Interchangeability of Polyadenylation Signals in Saccharomyces cerevisiae", Mol. and Cell Biology, Vol. 14, No. 7, 1994, pp. 4633-4642.					
		Henikoff, et al., "Transcription Terminates in Yeast Distal to a Control Sequence", Cell., Vol. 33, June 1983, pp. 607-614.					
		Hofmann, et al., "Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-Like Particles in Saccharomyces cerevisiae", Virology, Vol. 209, 1995. pp. 506-518.					
		Jansen, et al., "Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papillomavirus formation", Vaccine, Vol. 13, No. 16, 1995, pp. 1509-1514.					
		Kirii, et al., "Human Papillomavirus Type 58 DNA Sequence", Virology, Vol. 185, 1991, pp. 424-427.					
		Kotula, et al., "Evaluation of Foreign Gene Codon Optimization in Yeast: Expression of a Mouse IG Kappa Chain", Biotechnology, Vol. 9, December 1991, pp. 1386-1389.					
		Liu, et al., "Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhanced prophylactic and therapeutic efficacy", Vaccine, Vol 20, 2002, pp. 862-869.					
		McMurray, et al., "Biology of human papillomaviruses", J. Exp. Path., Vol. 82, 2001, pp. 15-33.					
		Russo, et al., "Saccharomyces cerevisiae mRNA 3' End Forming Signals are also Involved in Transcription Termination", Yeast, Vol. 11, 1995, pp. 447-453.					
		Schiffman, et al., "Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia", J. of National Cancer Inst., Vol. 85, Vol 12, 1993, pp. 958-964.					

			
Examiner Signature		Date Considered	

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

	h - Nih - Na - Kara Karan - A A A D D (D T O				COMPLETE IF KNOWN
INFORMATION DISCLOSURE				Application Number	To Be Assigned Did DU DI DI
				Filing Date	May 11, 2006
3	STATEMENT BY APPLICANT		First Named Inventor		
				Group Art Unit	
(use as many sheets as necessary)			ecessary)	Examiner Name	
Sheet	3	of	3	Attorney Docket Number	21561P

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
	_	Schiller, et al., "Papillomavirus-Like Particles: Basic and Applied Studies", UK: Leeds Medical Information, 1996, pp. 101-112.					
		Schiller, et al., "Papillomavirus-Like Particle Vaccines", J. Natl. Cancer Inst. Monographs, No. 28, 2000, pp. 50-54.					
		Schiller, et al., "Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report", J. of Clin. Virology., Vol 19, 2000, pp. 67-74.					
		Sharp, et al., "Synonymous Codon Usage in Saccharomyces cerevisiae", Yeast, Vol. 7, 1991, pp. 657-678.					
		Suzich, et al., "Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas", PNAS USA, Vol. 92, December 1995, pp. 11553-11557.					
		Thalenfeld, et al., "oli 1 Transcripts in Wild Type and in a Cytophasmic 'Petite' Mutant of Yeast*", J. of Biol Chem., Vol. 258, No. 23, December 10, 1983, pp. 14065-14065.					
		Tobery, et al., "Effect of vaccine delivery system on the induction of HPV 16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques", Vaccine, Vol. 21, 2003, pp. 1539-1547.					
		Zaret, et al., "DNA Sequence Required for Efficient Transcription Termination in Yeast", Cell, Vol. 28, March 1982, pp. 563-573.					
		Zaret, et al., "Mutationally Altered 3' Ends of Yeast CYC1 mRNA Affect Transcript Stability and Translational Efficiency", J. Mol. Biol., Vol. 176, 1984, pp. 107-135.					
		Zhou, et al., "Papillomavirus Capsid Protein Expression Level Depends on the Match Between Codon Usage and tRNA Availability", J. of Virol., Vol. 73, No. 6, June 1999, pp. 4972-4982.					
,							

Examiner Signature	Date Considered		